A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion
← catalyst calendarNCT06672523 · readout in 432 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
8estimated
Sites
3
Countries
Hungary, Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-24 | actual | When the study began enrolling |
| Primary completion | 2027-10-25 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-25 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors With Homozygous MTAP Deletion
Interventions
- Drug: BMS-986504
- Drug: [14C]-BMS-986504
Primary outcomes
what the primary-completion date above is the date OFMaximum observed concentration (Cmax)
measured Up to 2 weeks
Time of maximum observed drug concentration (Tmax)
measured Up to 2 weeks
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))
measured Up to 2 weeks
Area under the concentration-time curve from time zero extrapolated to infinite time (AUC(INF))
measured Up to 2 weeks
Terminal elimination half-life (T-HALF)
measured Up to 2 weeks
Apparent total body clearance (CLT/F)
measured Up to 2 weeks
Apparent volume of distribution during the terminal phase (Vz/F)
measured Up to 2 weeks
Percentage of estimated part for the calculation of AUC(INF) (%AUC(INF))
measured Up to 2 weeks
Blood-to-plasma total radioactivity (TRA) ratio
measured Up to 2 weeks
Total amount of administered dose recovered in urine (UR)
measured Up to 2 weeks
Percent of administered dose recovered in urine (%UR)
measured Up to 2 weeks
Renal clearance (CLR) in urine
measured Up to 2 weeks
Total radioactivity in UR
measured Up to 2 weeks
Total radioactivity in %UR
measured Up to 2 weeks
Total radioactivity in total amount of administered dose recovered in feces (FR)
measured Up to 2 weeks
Total radioactivity in percent of administered dose recovered in feces (%FR)
measured Up to 2 weeks
Total amount of radioactivity recovered (Rtotal)
measured Up to 2 weeks
Total percent of radioactivity recovered (%TOTAL)
measured Up to 2 weeks
TRA amount recovered and fraction of the radioactive dose in vomit if applicable
measured Up to 2 weeks
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed